RecruitMe Clinical Trial

Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients with Previously Treated Lyme
A New Treatment Study for Previously Treated Lyme Disease Patients with Persistent Fatigue
Sponsor:Columbia Lyme & Tick-Borne Diseases Research Center
Enrolling:Male and Female Patients
Study Length:98 Days
Clinic Visits:8
Age Range:Between 18 and 65 years old
IRB Number:7755
U.S. Government ID:NCT03891667
Contact: Lyme Center: 646-774-7503 / lymecenter@cumc.columbia.edu
Additional Study Information:

Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as "Antabuse", has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known, FDA approved drug is currently used to help individuals with alcohol dependence resist consumption; however, new scientific research has demonstrated that disulfiram is a potent killer of the Lyme bacteria in the laboratory setting. The primary goals of this study are to assess safety, side-effects, and effectiveness of disulfiram in reducing symptoms in patients with post-treatment Lyme symptoms. This study will take place over the course of 16 weeks with 8 in-person visits to our Lyme Center and several phone follow-ups. Participants will be placed on either a 4-week or 8-week, daily disulfiram treatment regimen.

Do You Qualify?
Between the ages 18-65?YesNo
Diagnosed with Lyme Disease within the past 8 years?YesNo
Willing to provide records of positive Lyme tests?YesNo
Treated with Antibiotics for Lyme Disease?YesNo
Able to come to New York City for 8 research visits?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Lyme Center
Email: lymecenter@cumc.columbia.edu
Phone: 646-774-7503